So powerful, they feel self-propelled A whole new way to deep clean from Oreck® A fresh take on cleaning the air Our connection is our customers. At Oreck®, we’re here to help every step of the way. From helping you choose the best machine for you, to buying your next cleaner, we promise to not only provide the quality service you’ve depended on, but also give you the best reliability and performance that only an Oreck can give. It all began with one man and his revolutionary vision... Founded by David Oreck in 1963, Oreck Corporation began as a manufacturer of upright vacuum cleaners for the U.S. hotel industry. Today the company produces and sells vacuums, steam mops, floor machines, air purifiers and cleaning products for use in hotels and homes throughout the U.S., Canada and Europe. Daikin Industries, Ltd. (ダイキン工業株式会社 Daikin Kōgyō Kabushiki-gaisha?) is a Japanese multinational air conditioner manufacturing company headquartered in Osaka.

It has operations in Japan, China, Australia, India, Southeast Asia, Europe, North America, and South America. Daikin is the inventor of variable refrigerant volume systems (or VRV by Daikin air conditioning, other manufacturers remarked this as VRF) and an innovator in the split system air conditioning market. Daikin codeveloped a R-410A refrigerant with Carrier. Daikin entered the North American air conditioning market in 2004. Daikin Industries Ltd was founded in 1924 as Osaka Kinzoku Kogyosho LP by Akira Yamada. In 1953, Daiflon or polychlorotrifluoroethylene was developed. In 1963 the company was renamed Daikin Kogyo Co Ltd and developed Neoflon. In 1982 it was renamed to the current Daikin Industries Ltd. In November 2006 Daikin purchased OYL Industries. This made Daikin the second largest HVAC manufacturer in the world after Carrier Corporation. In 2008 Daikin purchased a 75% share of All World Machinery Supply based in Roscoe, Illinois.[5] using technology from their Air Conditioning division.

Facing the global demands on CO2 reductions and the serious energy issues facing the world, this product aims to cut energy consumption[] in the manufacturing sector. As of April 2014, Daikin Hydraulics marketed a line of piston pumps, vane pumps, manual pumps, solenoid valves, and flow and control valves claiming their pump technology to be 50–70 percent more energy efficient than conventional technology. In August 2012 Daikin agreed to acquire Goodman Global from the San Francisco-based private equity firm Hellman & Friedman for $3.7 billion,[7] after first planning to buy Goodman the previous year. In January 2011, Daikin had announced plans to buy Goodman Global at approximately US $4 billion valuation,[8] however, the plans were put off following the 2011 Tōhoku earthquake and tsunami[9] The acquisition was expected to expand Daikin's presence in the United States and in duct-type and split-system air-conditioners, and was expected to make Daikin the world's largest maker of heating

, ventilation and air-conditioning systems. Daikin opened its first American air-conditioner manufacturing facility—employing about 250 people in a 525,000 square feet (48,800 m2) facility in Houston, Texas—in 2013. Daikin is the official sponsor of Belgian soccer team Club Brugge and of Galatasaray Daikin women's volleyball team. Daikin is organised into the following divisions, offering the following products:[1][15]heigoo air purifier ^ Daikin developed the hybrid hydraulic systems[]gillece air duct cleaning ^ Japan's Daikin eyes Goodman Global; flixonase ionising air purifierdeal could cost $4 bln ^ Daikin says puts efforts to buy Goodman Global on holdHOME > VENUE SEARCH > BlueWave Inn Yotsubashi : 06-6543-4284 : 06-6543-2850

〒550-0013 1-4-12 Shinmachi, Nishi-ku, Osaka City This hotel situated directly above Yotsubashi Station on the Subway Yotsubashi line is ideally located for both business and pleasure. The rooms are fitted with air purifiers and Simmons beds. With a mostly female staff to look after guests and full security, female guest can stay with a peace of mind. Shinsaibashi Station (Subway Midosuji Line) or Exit 1-A Yotsubashi Station (Subway Yotsubashi Line) Kita (City North) Area Minami (City South) Area Kansai Int'l Airport Area Eisai Co., Ltd. (エーザイ株式会社 Ēzai Kabushiki-gaisha?) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[3] The American subsidiary of the company, Eisai Inc., was established in 1995.

In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson. In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals. In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases. In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for $3.9 billion USD. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio. In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel.

Eisai head office in Tokyo Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary Eisai Inc. is headquartered in Woodcliff Lake, New Jersey. Eisai maintains medical research headquarters in Woodcliff Lake, New Jersey as well as locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute is based. The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region. Some of the key products that Eisai produces or markets with partners include: Aricept accounted for 40% of Eisai's revenue as of March 2010.[6] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[6] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.